Athelas Stock
Athelas - rapid diagnostics through Deep Learning.
Sign up today and learn more about Athelas Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Athelas Stock
Athelas utilizes deep learning and computer vision to rapidly analyze tissue samples for diagnostics. The product is used for immune monitoring, blood counts, and parasite diagnostics.
Funding History
| February 2016 | $0 |
|---|---|
| August 2016 | $120K |
| January 2017 | $3.5M |
Management
Founder
Tanay Tandon
Product Manager
Steve Moffatt
Press
fiercehealthcare - Feb, 2 2022
RPM tech provider Athelas hits unicorn status with $132M raised for chronic care managementlivemint - Jan, 31 2022
Health startup Athelas its $1.5 billion valuation after pandemic boomLaboratory News - May, 11 2018
New At-Home CBC Device Enables Complete Blood Testing for Cancer Treatments and Biological/Viral Monitoring - DARKDaily.comnanalyze - Jan, 8 2018
6 Blood Testing Startups to be the Next TheranosMedgadget (blog) - Sep, 6 2017
Athelas Device Provides Accurate CBC Testing – From HomeDigital Trends - Aug, 29 2017
Test your blood from the comfort of your home with AthelasTechCrunch - Aug, 28 2017
Athelas launches a new type of blood testing device for the homeEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase
EquityZen Recognized As:
